[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-injury":205},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,82,114,156,181],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100586097",false,"NCT06910943","Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support","A Phase 2b\u002F3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Choline Chloride for Injection (Low Dose and High Dose) Versus Placebo in Adolescents and Adults With Intestinal Failure Receiving Long-Term Parenteral Support","THRIVE-3","Key Inclusion Criteria:\n\n* Male or female 12 years of age or older at the time of signing the informed consent\n* Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements, prior to study entry\n* Individuals with intestinal failure receiving long-term PS when oral or enteral nutrition is not possible, insufficient, or contraindicated who are receiving stable PS at time of screening and for the duration of the study; Note: Long-Term PS = Participant must have been receiving PS for at least 6 months prior to screening and requiring PS at least 3 times per week\n* Females of childbearing potential must have a negative urine pregnancy test at screening\n\nKey Exclusion Criteria:\n\n* Patients taking steatogenic medications for ≥ 12 weeks in the past 12 months; those taking any medicine that could affect the measurement of hepatic steatosis within 12 weeks prior to study entry\n* Evidence of systemic active infection at the time of dosing\n* Participants intending to take non-study drug choline supplements or choline-containing multivitamins during the course of the study\n* Participants unwilling to limit alcohol intake to no more than 20\u002Fg a day for 24 hours prior to their screening visit and for the duration of the study\n* Active malignancy (excluding basal cell skin tumor, low or very low risk prostate cancer, cervical carcinoma in situ and local resected cervical cancer)\n* Clinically significant renal disease\n* Low B12 or low serum folic acid levels that are less than the normal range\n* Fulminant liver failure, with active bleeding and\u002For encephalopathy","ALL","12 Years",{"count":19,"type":20},129,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","TARA-001-301 is a Phase 2b\u002F3 randomized Open-Label Dose-Selection study with an Open-Label Extension and randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to investigate the safety and efficacy of Choline Chloride for Injection (Low Dose and High Dose) versus Placebo in adolescents (ages 12 to \\\u003C 18 years of age) and adults (≥ 18 years of age) with intestinal failure receiving long-term PS when oral or enteral nutrition is not possible, insufficient, or contraindicated.\n\nParticipants will be enrolled in one of 2 parts, each part will be followed by an open-label extension period of approximately a year.\n\nPart 1: Open-Label Dose-Selection Phase Part 2: Double-Blind, Placebo-Controlled Phase\n\nThe purpose of the Open-Label Dose-Selection Phase is to evaluate the safety, tolerability, how Choline Chloride for Injection (study drug) is distributed in the body, and to select 2 of 3 doses for testing in the Double-Blind, Placebo-Controlled Phase.\n\nThe purpose of the Double-Blind, Placebo-Controlled Phase is to assess the safety of the study drug and how well the study drug works at the 2 selected dose levels.",[27,28],"Choline Deficiency","Liver Injury",[30,31,32,33,34],"Intestinal Failure","Parenteral Nutrition","Parenteral Support","Choline Chloride","choline deficiency","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":39},"2025-12-10",{"date":43,"type":20},"2028-06",{"name":45,"class":46},"Protara Therapeutics","INDUSTRY",17,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100582528","NCT06864481","Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis","Description, Course and Treatment of Immune Checkpoint Inhibitor-induced Hepatitis","CO-CHILI","Inclusion criteria:\n\n* Age ≥ 18 years\n\n  * Patient willing to participate in the study\n  * Patient with cancer receiving neoadjuvant, adjuvant, or maintenance treatment · Patient treated with ICI, either as monotherapy or in combination with another antitumor treatment (targeted therapy, chemotherapy, or radiotherapy), either de novo or after a first-line treatment including ICIs\n  * Patient who has received at least one injection of an ICI ·\n  * Onset of hepatitis following treatment initiation, defined by the following criteria:\n\n    * ALT (alanine aminotransferase) ≥ 5 times the upper normal limit\n    * ALP (alkaline phosphatase) ≥ 2 times the upper normal limit\n    * ALT (alanine aminotransferase) ≥ 3 times the upper normal limit and bilirubin ≥ 2 times the upper normal limit ·\n  * Patient with grade 3 or 4 hepatitis, according to the current CTCAE classification\n  * Exclusion criteria:\n* Patient with another cause of acute hepatitis, including viral, autoimmune, ischemic, acute alcoholic hepatitis, or Wilson's disease.\n* Patient unable to express their non-opposition to participate in the study.\n* Person deprived of liberty, under guardianship or curatorship, or in an emergency situation.\n* Person not affiliated with a social security system or without entitlement to healthcare coverage.","18 Years",{"count":57,"type":20},250,"12 Months","OBSERVATIONAL","Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors. While effective, they can cause immune-related side effects, including liver inflammation (ICI-induced hepatitis or CHILI), which affects up to 25% of patients. Severe cases requiring treatment discontinuation are rare but challenging to manage.\n\nStudy Objective This multicenter prospective study aims to better understand CHILI, its clinical patterns, treatment response, and risk of recurrence. It will focus on different types of liver injury (cholestatic, hepatocellular, or mixed) to guide better treatment decisions.\n\nInnovation and Approach Currently, there is no clear consensus on how to manage CHILI or when to safely restart immunotherapy. This study will collect real-world data from adult patients treated with ICIs, following international guidelines or a pragmatic approach when no consensus exists. Findings will help improve care strategies for patients experiencing ICI-related liver toxicity.",[28,62,63],"Secondary to Immune Checkpoint Inhibitors","Cancer Patients",[65,66,67,68,69,70],"Immune checkpoint inhibitors","Immunotherapy","Drug-induced liver injury","Hepatitis","Cholangitis","Ursodeoxycholic acid","2026-06-17",{"date":73,"type":39},"2026-06-18",{"date":75,"type":39},"2025-04-22",{"date":77,"type":20},"2028-04-22",{"name":79,"class":80},"University Hospital, Montpellier","OTHER",1,{"id":83,"slug":4,"hasResults":10,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":10,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":99,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100535953","NCT06258525","SAMe in Prevention of Oxaliplatin-associated Liver Injury","A Phase II, Open-Label Trial of S-Adenosylmethionine (SAMe) in Prevention of Oxaliplatin Associated Liver Injury","Inclusion Criteria:\n\n* Stage IV patients with resectable liver predominant metastatic colorectal cancer (new diagnosis or recurrent) referred to Cedars Sinai Medical Center for oxaliplatin based systemic therapy.\n* Age ≥ 18 years.\n* Patients who are planning to undergo liver resection following oxaliplatin based chemotherapy treatment.\n* ECOG Performance Status 0-2 or Karnofsky Performance Status (KPS) ≥ 60%.\n* Demonstrate adequate organ and marrow function (within 28 days of study treatment initiation)\n* Female subjects of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to receiving the first dose of study medication for eligibility verification purposes. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Female subjects of childbearing potential should be willing to use adequate methods of birth control (hormonal or barrier method of birth control) or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year.\n* Male subjects should agree to use an adequate method of contraception starting with the first dose of therapy through 120 days after the last dose of therapy.\n* Subjects taking vitamin E ≥800 IU\u002Fday must be on a stable dose defined as:\n\n  1. No changes in prescribed dose within 180 days of the screening visit and\n  2. No new vitamin E-containing medications within 180 days of the screening visit or\n  3. Discontinuation of vitamin E ≥800 IU\u002Fday for at least 180 days prior to the screening visit.\n* Subjects taking anti-diabetic medications must be on a stable dose for at least 90 days prior to the date of the screening visit.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.\n* No other anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) or investigational agent may be used from 28 days prior to registration and until the end-of-study visit.\n* Has previously received chemotherapy for metastatic disease (neoadjuvant or adjuvant therapy is allowed as long as treatment was completed ≥6 months prior to recurrence).\n* Has pre-existing grade ≥ 3 neuropathy precluding use of oxaliplatin.\n* Has known additional malignancy that is progressing or requires active treatment.\n* Has a known hypersensitivity to any of the study supplement\u002Fdrugs (SAMe, oxaliplatin, flourouacil, folinic acid and capecitabine).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has any gastrointestinal disorder (e.g., bowel obstruction) or neurologic condition (e.g., oropharyngeal dysphagia) that may result in impairment of oral intake, inability to swallow the oral supplement, and\u002For impairment of absorption of study drug in the opinion of the treating investigator.\n* Has previous clinical diagnosis of cirrhosis, has had known history of Hep A\u002FB\u002FC or nonalcoholic fatty liver disease (NAFLD), liver transplantation, or any other cause for decompensated liver disease.\n* Known human immunodeficiency virus (HIV) infection.\n* Any of the following within 6 months prior to the screening visit: unstable cardiovascular disease, myocardial infarction, coronary artery bypass surgery, coronary angioplasty, transient ischemic attack, or cerebrovascular accident.\n* Any other condition that, in the investigator's opinion, would impede competence or compliance or delay completion of the study.\n* History of Parkinson's disease or bipolar disorder.\n\nPatients taking the following prohibited medications:\n\n* Olanzapine\n* MAO inhibiters, including:\n\n  * Isocarboxazid\n  * Linezolid\n  * Methylene blue injection\n  * Phenelzine\n  * Rasagiline\n  * Selegiline\n  * Tranylcypromine\n  * Any other MAO inhibitors The above prohibited medications cannot be taken -14 days prior to Day 0 and during study treatment.. Patients currently on or plan to be prescribed anti-psychotic medications not listed above may be excluded at the discretion of the Investigator. - Active infection as evidenced by positive urine culture, blood culture, or pneumonia.",{"count":89,"type":20},30,[23],"This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.",[93,94,95,28,96,97,98],"Colorectal Cancer","Liver Metastases","Liver Metastasis Colon Cancer","Sinusoidal Obstruction Syndrome","5-Fluorouracil Toxicity","Liver Toxicity, Chemically-Induced",[100,101,102],"S-adenosylmethionine","Oxaliplatin","Stage IV colorectal cancer","NOT_YET_RECRUITING","2026-05-01",{"date":106,"type":39},"2026-05-06",{"date":108,"type":20},"2026-07",{"date":110,"type":20},"2028-08",{"name":112,"class":80},"Cedars-Sinai Medical Center",2,{"id":115,"slug":4,"hasResults":10,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":122,"conditions":123,"keywords":137,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":81},"100434493","NCT04937868","Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients","NEXUS AP CT","Inclusion Criteria:\n\nBlunt trauma patients who undergo abdominal-pelvic CT imaging during their initial trauma evaluation in the emergency department.\n\nExclusion Criteria:\n\nNone",{"count":121,"type":20},12000,"Unrecognized abdominal and pelvic injuries can result in catastrophic disability and death. Sporadic reports of \"occult\" injuries have generated concern, and physicians, fearing that they may miss such an injury, have adopted the practice of obtaining computed tomography on virtually all patients with significant blunt trauma. This practice exposes large numbers patients to dangerous radiation at considerable expense, while detecting injuries in a small minority of cases.\n\nExisting data suggest that a limited number of criteria can reliably identify blunt injury victims who have \"no risk\" of abdominal or pelvic injuries, and hence no need for computed tomography (CT), without misidentifying any injured patient. It is estimated that nationwide implementation of such criteria could result in an annual reduction in radiographic charges of $75 million, and a significant decrease in radiation exposure and radiation induced malignancies.\n\nThis study seeks to determine whether \"low risk\" criteria can reliably identify patients who have sustained significant abdominal or pelvic injuries and safely decrease CT imaging of blunt trauma patients. This goal will be accomplished in the following manner:\n\nAll blunt trauma victims undergoing computed tomography of the abdomen\u002Fpelvis in the emergency department will undergo routine clinical evaluations prior to radiographic imaging. Based on these examinations, the presence or absence of specific clinical findings (i.e. abdominal\u002Fpelvic\u002Fflank pain, abdominal\u002Fpelvic\u002Fflank tenderness, bruising abrasions, distention, hip pain, hematuria, hypotension, tachycardia, low or falling hematocrit, intoxication, altered sensorium, distracting injury, positive FAST imaging, dangerous mechanism, abnormal x-ray imaging) will be recorded for each patient, as will the presence or absence of abdominal or pelvic injuries. The clinical findings will serve as potential imaging criteria. At the completion of the derivation portion of the study the criteria will be examined to find a subset that predicts injury with high sensitivity, while simultaneously excluding injury, and hence the need for imaging, in the remaining patients. These criteria will then be confirmed in a separate validation phase of the study.\n\nThe criteria will be considered to be reliable if the lower statistical confidence limit for the measured sensitivity exceeds 98.0%. Potential reductions in CT imaging will be estimated by determining the proportion of \"low-risk\" patients that do not have significant abdominal or pelvic injuries.",[124,125,126,127,128,28,129,130,131,132,133,134,135,136],"Abdominal Injury","Pelvic Fracture","Genital Hemorrhage","Lumbar Spine Injury","Hip Injuries","Spleen Injury","Renal Injury","Diaphragm Injury","Aortic Rupture","Aortic Dissection","Bowel Disease","Vascular System Injuries","Sacral Fracture",[138,139,140,141,142,143,144,145,146],"Blunt trauma","Abdominal injury","Pelvic injury","Spine injury","Genital injury","Vascular injury","Hip injury","Computed tomography","Decision instrument","2026-01-09",{"date":149,"type":39},"2026-01-13",{"date":151,"type":39},"2018-01-15",{"date":153,"type":20},"2027-06-15",{"name":155,"class":80},"University of California, Los Angeles",{"id":157,"slug":4,"hasResults":10,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":16,"minAge":55,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":81},"100451196","NCT05155358","Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke","Inclusion Criteria:\n\n1. The patient voluntarily signs an informed consent form;\n2. Adult patients who meet the criteria for heat stroke;\n3. Heat stroke is defined as heat stroke (Heat Stroke, HS) is a serious fatal disease caused by heat injury factors acting on the body, accompanied by multiple organ damage.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years old or \\>90 years old;\n2. Patients with advanced tumors, Pregnancy or lactation;\n3. Patients who missed out during treatment and whose data are incomplete.",true,"90 Years",{"count":164,"type":20},150,"Heat stroke is a clinical syndrome with high incidence and high fatality rate in summer. Patients with liver, kidney, and brain damage are prone to secondary MODS, and the prognosis is poor due to high medical costs. At present, there is no unified diagnostic criteria for acute liver injury associated with heat stroke, and the commonly used prognosis scores are rarely included in liver injury indicators, which is not good for practicality.",[167,168,169,170,28,171],"Heat Stroke","Early Waking","MODS","Proteinosis","Kidney Injury","2025-08-10",{"date":174,"type":39},"2025-08-14",{"date":176,"type":20},"2025-08-31",{"date":178,"type":20},"2027-12-31",{"name":180,"class":80},"Xijing Hospital",{"id":182,"slug":4,"hasResults":10,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":10,"sex":16,"minAge":55,"maxAge":186,"enrollmentInfo":187,"targetDuration":189,"studyType":59,"phases":4,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":81},"100596828","NCT07050550","A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury","Inclusion Criteria:\n\n* 1\\) Aged between 18 and 80 years old; 2) Clinically diagnosed with liver damage (combined with medical history and laboratory tests, manifested as changes in liver enzymes, abnormal bilirubin metabolism, dysfunction of substance synthesis, and decreased biodegradation function, including indicators such as ALT, AST, ALP, GGT, albumin (Alb), TBil, and DBil); 3) Clinically diagnosed with liver failure (liver failure is a severe liver damage caused by multiple factors, resulting in severe dysfunction or decompensation of its synthesis, detoxification, excretion, and biotransformation functions, and a group of clinical syndromes with coagulation dysfunction, jaundice, hepatic encephalopathy, ascites, etc. as the main manifestations. Key points for the diagnosis of liver failure (a) Extreme fatigue, and severe gastrointestinal symptoms such as anorexia, vomiting, and abdominal distension; (b) Progressive deepening of jaundice (serum TBil ≥171μmol\u002FL or daily increase ≥17.1μmol\u002FL); (c) Bleeding tendency, plasma prothrombin activity (PTA≤40% or international normalized ratio (INR ≥ 1.5; (d) hepatic encephalopathy (grade II or above) or other complications.); 4) informed consent and able to accept follow-up, can understand and comply with the requirements of the study\n\nExclusion Criteria:\n\n* 1\\) Patients with serious primary diseases of the heart, brain, kidney and hematopoietic system (i.e. Weber heart function grade D; hemoglobin (Hb) \\\u003C10 g\u002FdL, white blood cells (WBC) \\\u003C3×109\u002FL, platelets (PLT) \\\u003C90×109\u002FL; creatinine clearance (CrCl) \\\u003C40 mL\u002Fmin); 2) Patients with mental disorders or primary affective disorders; 3) Patients who cannot understand, follow the study protocol or sign the informed consent form; 4) Patients with contraindications to PET imaging (including pregnant women, breastfeeding women, women of childbearing age who have plans to have children in the near future, etc.); 5) Patients with allergies to imaging agents; 6) Patients who cannot cooperate with PET scanning due to hypoglycemia, severe pain or tremor.","80 Years",{"count":188,"type":20},45,"6 Months","This study is a prospective exploratory clinical study aimed at evaluating the efficacy (sensitivity, specificity) of 18F-DFA PET imaging in assessing liver function damage. Subjects who meet the inclusion criteria are screened and enter this study to receive 18F-DFA PET imaging assessment, with clinical biochemical liver function indicators or liver puncture pathological examination as controls.",[28],[193,194,195],"liver injury","pet-ct","18F-DFA","2025-06-26",{"date":198,"type":39},"2025-07-03",{"date":200,"type":39},"2024-12-01",{"date":202,"type":20},"2025-12-31",{"name":204,"class":80},"First Affiliated Hospital of Zhejiang University",""]